ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24257
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24257

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment - DS1062-328

 

Disease Types: Genitourinary Cancer Research

Eligibility Requirements:

• Histologically or cytologically confirmed unresectable locally
advanced or metastatic urothelial carcinoma of the bladder,
renal pelvis, ureter, or urethra
• Subjects must be considered eligible to receive cisplatin- or
carboplatin-containing therapy
• Must have experienced radiographic progression or relapse
during or after 1L of EV/pembrolizumab
• Subjects that received prior therapy other than
EV/pembrolizumab combo are excluded
• Subjects with history of allogenic transplant or prior TROP2
directed ADC therapy are excluded

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates